Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nesiritide for recovery after Fontan surgery
NCT03207295Unknown
- Sponsor
- National Center for Cardiovascular Disease
- Start
- Jul 2017
- Primary completion
- Jul 2020
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Randomised, single-blind trial of nesiritide in congenital heart disease (CHD) (2 arms), sponsored by National Center for Cardiovascular Disease. Primary endpoint: Days of chest drainage at 18 weeks. Status: unknown.
02
Drugs
nesiritide
03
Conditions
congenital heart disease (CHD)
Beyond the preview
Go deeper on NCT03207295.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03207295.